Bioqual(OTC) BIOQ

Bioqual, Inc. is a leading provider of preclinical research solutions, specializing in both in-vivo and in-vitro methodologies. The company serves a diverse clientele, including commercial enterprises and government agencies, focusing on critical health domains such as COVID-19, AIDS, and oncology.

Products and Services

• Preclinical research solutions for various health domains
• Advanced laboratory capabilities, including biological sample processing
• Support for studies utilizing animal research models

Growth Outlook

• Revenue of $9.27 million reported in the latest quarter
• Strong cash position with $11.12 million in cash and equivalents
• Current ratio of 4.22 indicates robust liquidity

Financial Highlights

• Trailing twelve months (TTM) revenue of $39.8 million
• Net income margin of -10.43% reflects ongoing investment in growth
• Operating cash flow of $221,438 in the latest quarter

Bioqual, Inc. has established itself as a key player in the medical diagnostics and research industry. The company's focus on preclinical research solutions positions it well to capitalize on the growing demand for innovative health solutions. Recent financial performance indicates a solid revenue stream, with a TTM revenue of $39.8 million, showcasing the company's ability to generate income despite challenges. The latest quarterly report highlighted a revenue of $9.27 million, reflecting a consistent demand for its services. The company's liquidity is strong, as evidenced by a current ratio of 4.22, which suggests that it can easily meet its short-term obligations. Additionally, the cash position of $11.12 million provides a buffer for future investments and operational needs. Although the net income margin remains negative at -10.43%, this is indicative of ongoing investments aimed at long-term growth rather than immediate profitability. Overall, Bioqual, Inc. presents a compelling opportunity for investors interested in the healthcare sector, particularly in the realm of preclinical research and diagnostics. The company's established expertise and strong financial position may offer a foundation for future growth and innovation.